CHEST Online Supplement

The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer

An Analysis Based on Individual Participant Data

Neal Navani, MD, PhD; David J. Fisher, MSc; Jayne F. Tierney, PhD; Richard J. Stephens; and Sarah Burdett, MSc; on behalf of the NSCLC Meta-analysis Collaborative Group

e-Table 1.

Comparison of TNM staging systems

4th edition (1987)(29)		5th edition (1997)(30), 6th edition (2002)(31)	
Stage I	T1,N0,M0	Stage IA	T1,N0,M0
	T2,N0,M0	Stage IB	T2,N0,M0
Stage II	T1,N1,M0	Stage IIA	T1,N1,M0
	T2,N1,M0		T2,N1,M0
		Stage IIB	T3,N0,M0
Stage IIIA	T1,N2,M0	Stage IIIA	T1,N2,M0
	T2,N2,M0		T2,N2,M0
	T3,N0/1/2,M0		T3,N1/2,M0
	anyT,N3,M0		anyT,N3,M0
Stage IIIB	T4,anyN,M0	Stage IIIB	T4,anyN,M0
Stage IV	anyT, anyN, M1	Stage IV	anyT,anyN,m1

e-Figure 1. Flowchart describing clinical and pathological agreement, clinical over staging and clinical under staging

All patients
n=698 (100%)

Clinically understaged
n=236 (34%)

Agreement
n=362 (52%)

Clinically overstaged
n=100 (14%)

cT < pT	cN < pN	Both	pM1
n=75 (32%)	n=100 (42%)	n=41 (17%)	n=20 (8%)

cT > pT	cN > pN	Both
n=17 (17%)	n=72 (72%)	n=11 (11%)

cN > pN
n=4 (5%)

cT > pT
n=9 (9%)

cN < pN
n=1 (6%)

cT < pT
n=4 (6%)

Unforeseen pN2+
n=103 (44% of 236)
of which:
n=10 (10%) pM1
n=25 (24%) both cT < pT and cN < pN
n=7 (7%) cT > pT

e-Table 2.

Multivariate logistic regression; Factors that may predict staging agreement

Predictor	TNM stage	
	χ^2 (df)	p-value
Histology	0.40 (2)	0.82
Staging method	1.01 (1)	0.32
Age	2.48 (1)	0.12
Gender	0.24 (1)	0.62
Overall*	**4.22 (5)**	**0.52**

"Overall" compares the model with all covariates entered to the null model

Sensitivity analysis with staging method replaced with year of accrual:

Predictor	TNM stage	
	χ^2 (df)	p-value
Histology	0.48 (2)	0.79
Year of randomisation	0.00 (1)	0.98
Age	2.55 (1)	0.11
Gender	0.19 (1)	0.66
Overall*	**3.21 (5)**	**0.67**

181248